Hepatitis B virus (HBV) (HBV)

The Hepatitis B virus (HBV) antigen expression machinery encompasses the viral and host factors responsible for producing viral proteins, primarily in the context of chronic infection (Seeger & Mason, 2000, Microbiology and Molecular Biology Reviews). HepG2 2.2.15 is a specialized human hepatoma cell line containing integrated HBV DNA dimers, which serves as a robust model for studying viral replication and evaluating antiviral agents (Sells et al., 1987, PNAS). The expression process involves the transcription of viral mRNAs by host RNA polymerase II from either integrated DNA or covalently closed circular DNA (cccDNA), followed by translation into proteins like the surface antigen (HBsAg) and e-antigen (HBeAg) (Levrero & Zucman-Rossi, 2016, Journal of Hepatology). Chronic expression of these antigens is a hallmark of HBV infection and is linked to immune evasion, liver inflammation, and the progression to hepatocellular carcinoma (Liang, 2009, Hepatology). Therapeutic interventions targeting this machinery include nucleos(t)ide analogs that inhibit the viral polymerase and experimental RNA interference (RNAi) therapies designed to degrade viral transcripts (Wooddell et al., 2017, Molecular Therapy). The input name refers to a specific cell-based assay system rather than a single molecular target.

Other names

HBV replication machineryHepG2 2.2.15 HBV expression systemHepatitis B virus antigen expressionHBV cccDNA transcription complex

Inhibition of HBV DNA polymerase (reverse transcriptase); degradation of viral RNA via RNA interference; inhibition of viral entry; modulation of host immune response.